Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01

Lee, Jong Hoon; Lee, Sea-Won; Kim, Ju Ree; Kim, Yeon Sil; Yoon, Myung Ha; Jeong, Sungmoon; Kim, Jin Hee; Lee, Ja Young; Eom, Keun Yong; Jeong, Bae Kwon; Lee, Seok Ho

doi:10.1016/j.ygyno.2017.09.036

Cited by 32 publications

(33 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All conventional diagnostic imaging methods yield information on primary tumor size, and a large tumor has long been known to predict advanced stage and poor prognosis in cervical cancer (Table 2) [45, 62•, 63]. Two recent studies have found that primary tumor size > 20.5 mm predicts deep stromal invasion [38] and that primary tumor size > 30 mm predicts parametrial invasion [45].…”

Section: Imaging Biomarkersmentioning

confidence: 99%

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

et al. 2019

View full text Add to dashboard Cite

Purpose of Review For uterine cervical cancer, the recently revised International Federation of Gynecology and Obstetrics (FIGO) staging system (2018) incorporates imaging and pathology assessments in its staging. In this review we summarize the reported staging performances of conventional and novel imaging methods and provide an overview of promising novel imaging methods relevant for cervical cancer patient care. Recent Findings Diagnostic imaging during the primary diagnostic work-up is recommended to better assess tumor extent and metastatic disease and is now reflected in the 2018 FIGO stages 3C1 and 3C2 (positive pelvic and/or paraaortic lymph nodes). For pretreatment local staging, imaging by transvaginal or transrectal ultrasound (TVS, TRS) and/or magnetic resonance imaging (MRI) is instrumental to define pelvic tumor extent, including a more accurate assessment of tumor size, stromal invasion depth, and parametrial invasion. In locally advanced cervical cancer, positron emission tomography-computed tomography (PET-CT) or computed tomography (CT) is recommended, since the identification of metastatic lymph nodes and distant metastases has therapeutic consequences. Furthermore, novel imaging techniques offer visualization of microstructural and functional tumor characteristics, reportedly linked to clinical phenotype, thus with a potential for further improving risk stratification and individualization of treatment. Summary Diagnostic imaging by MRI/TVS/TRS and PET-CT/CT is instrumental for pretreatment staging in uterine cervical cancer and guides optimal treatment strategy. Novel imaging techniques may also provide functional biomarkers with potential relevance for developing more targeted treatment strategies in cervical cancer.

show abstract

Section: Imaging Biomarkersmentioning

confidence: 99%

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Researchers have investigated the clinical significance of consecutively monitoring the level of serum SCC-Ag in cervical cancer patients during radiation/chemoradiation therapy [11,17,21]. Hashimoto et al evaluated the value of SCC-Ag as a predicator of chemotherapy response in patients with metastatic cervical cancer and concluded that a response to chemotherapy was possible for patients in whom SCC-Ag levels declined between the second and third cycles of chemotherapy [17].…”

Section: Discussionmentioning

confidence: 99%

“…The role of serum SCC-Ag in squamous cervical cancer has been extensively evaluated in previous works [4,7,8,[10][11][12][13][14][15][16][17][18][19][20][21][22][23][24], and several reviews and metaanalyses have been published in the literature [5,[25][26][27]. Most studies were of retrospective design and only detected SCC-Ag at one time-point.…”

Section: Introductionmentioning

confidence: 99%

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Sun

Kang

et al. 2020

BMC Cancer

View full text Add to dashboard Cite

Background: To study the kinetic profile and clinicopathological implications of squamous cell carcinoma antigen (SCC-Ag) in cervical cancer patients who underwent surgery by a self-developed SCC-Ag single molecule assay (Simoa) prototype immunoassay. Methods: Participants were prospectively enrolled between 04/2016 and 06/2017. Consecutive serum samples were collected at five points: day 0 (the day before surgery), postoperative day 4, weeks 2-4, months 2-4 and months 5-7. In total, 92 patients and 352 samples were included. The kinetic change in SCC-Ag levels and their associations with clinicopathological characteristics were studied. Results: Simoa SCC-Ag was validated by comparison with the Architect assay. SCC-Ag levels measured by the Simoa assay were highly correlated with the Architect assay's levels (Pearson's correlation coefficient = 0.979, Passing-Bablok regression slope 0.894 (0.847 to 0.949), intercept − 0.009 (− 0.047 to 0.027)). The median values for each time-point detected by the Simoa assay were 2.49, 0.66, 0.61, 0.72, and 0.71 ng/mL, respectively. The SCC-Ag levels decreased dramatically after surgery and then stabilized and fluctuated to some extent within 6 months. Patients with certain risk factors had significantly higher SCC-Ag values than their negative counterparts before surgery and at earlier time points after surgery, while no difference existed at the end of observation. Furthermore, although patients with positive lymph nodes had sustained higher SCC-Ag levels compared to those with negative lymph nodes, similar kinetic patterns of SCC-Ag levels were observed after surgery. Patients who received postoperative treatment had significantly higher SCC-Ag values than those with surgery only at diagnosis, while no difference existed after treatment. Conclusions: The Simoa SCC-Ag prototype was established for clinical settings. The SCC-Ag levels were higher in patients with risk factors, whereas the kinetic trend of SCC-Ag might be mainly affected by postoperative adjuvant therapy. These data indicate that the SCC-Ag level might be a good predictor for the status of cervical cancer, including disease aggressiveness and treatment response.

show abstract

“…Several studies have reported clinical response after radiation with or without concurrent chemotherapy based on RECIST, but none of them were specific for locally advanced cervical cancer. e rate of complete response reported was 17.3%-86.9% [21][22][23]. Low activity of Biocurcumin could be due to low intracellular concentrations because of pharmacokinetic factors.…”

Section: Discussionmentioning

confidence: 99%

Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double‐Blind Randomised Placebo‐Controlled Trial

Purbadi

Rustamadji

Prijanti

et al. 2020

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Cervical cancer is a leading cause of death among women worldwide, particularly in Indonesia. The main treatment of advanced-stage cervical cancer is radiation; however, the outcomes do not meet the required expectations. [1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5dione] has been reported in several studies for its potency in cancer therapy. This study aims to investigate the clinical and molecular [(malondialdehyde (MDA) and NF-κB levels] effects, apoptotic index, and safety of Biocurcumin (BCM-95) as a radiosensitiser in cervical cancer. In this double-blind placebo randomised-controlled trial, we randomised 121 patients into 2 groups (BCM-95 or placebo). MDA and their NF-κB levels and apoptotic index were measured before and after administering 24 Gy of radiation. MDA was identified using Wills’ method, whereas NF-κB was identified via ELISA. The apoptotic index was identified using TUNEL and DAPI staining. The clinical response was classified based on the RECIST. MDA levels before radiation were similar between both groups in per protocol and intention-to-treat (ITT) analyses (p=0.53 and p=0.16, respectively). After radiation, MDA levels increased in both groups with no significant differences in per protocol and ITT analyses (p=0.52 and p=0.18, respectively). NF-κB levels before radiation were similar between the two groups in per protocol and ITT analyses (p=0.92 and p=0.98, respectively). After radiation, the BCM-95 group showed an increase in the NF-κB levels compared with the placebo group in per protocol analysis but not in ITT analysis (p=0.018 and p=0.42, respectively). The BCM-95 group had a higher apoptotic index before radiation in per protocol analysis but not in ITT analysis (p=0.01 and p=0.61, respectively). After radiation, the apoptotic index remained higher in the BCM-95 group in per protocol analysis but not in ITT analysis (p=0.04 and p=0.91, respectively). There was no significant difference in complete response between the groups (per protocol, p=0.61; ITT analysis, p=0.90). Although BCM-95 can regulate ROS, NF-κB, and apoptosis in human cervical cancer, it is not significant. Therefore, BCM-95 does not improve clinical response to radiation treatment.

show abstract

Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01

Cited by 32 publications

References 34 publications

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

What Is the Role of Imaging at Primary Diagnostic Work-Up in Uterine Cervical Cancer?

The kinetic profile and clinical implication of SCC-Ag in squamous cervical cancer patients undergoing radical hysterectomy using the Simoa assay: a prospective observational study

Biocurcumin as Radiosensitiser for Cervical Cancer Study (BRACES): A Double‐Blind Randomised Placebo‐Controlled Trial

Contact Info

Product

Resources

About